PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



PEGs Conjugate a Versatile Approach of Antibody Drug .pdf


Original filename: PEGs Conjugate a Versatile Approach of Antibody Drug.pdf
Author: Administrator

This PDF 1.5 document has been generated by Microsoft? Office Word 2007, and has been sent on pdf-archive.com on 13/12/2019 at 07:23, from IP address 198.11.x.x. The current document download page has been viewed 52 times.
File size: 324 KB (3 pages).
Privacy: public file




Download original PDF file









Document preview


PEGs Conjugate a Versatile Approach of Antibody Drug
Antibody–drug conjugates (ADCs) consist of a desirable monoclonal antibody, a
potent cytotoxic drug, and an appropriate linker. They have gain popularity as an
innovative therapeutic approach for targeted cancer treatments. ADC linkers play key
roles in determining the pharmacokinetic properties, therapeutic index, selectivity
and the overall success of the ADC.

A properly selected linker helps the antibody to selectively deliver the cytotoxic drug
to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to
conjugation, the linkers play critical roles in ADCs’ stability during the preparation,
storage and ADC systemic circulation. The design of linkers for ADCs is challenging as
it has to meet stringent criteria of extracellular stability and intracellular release.
Intracellular acid and reducing environment, cathepsin enzymatic hydrolysis
environment can catalyze or activate the cleavage and release of the payload.
Nowadays, ADC linkers developed rapidly, it's covers DBCO, tetrazine, TCO, BCN and
cycloprpene etc., biotin linkers, PEG linkers, peptide linkers, glucuronide linkers,
photocleavable linkers, dye probe linkers, etc.
Being non-toxic and non-immunogenic, PEGs are very suitable for biological
applications, they can be added to media and attached to surfaces and conjugated to
molecules without interfering with cellular functions or target immunogenicities.
The useful characteristics of PEG Linkers have been increasingly recognized in
bioconjugation, biolabeling and ADC research and development. This is, in part, due

to their water solubility, lack of toxicity and well-defined chain lengths.
PEG-linkers are particularly attractive as a linker for conjugation. Water solubility, lack
of toxicity; low immunogenicity and well-defined chain lengths and molecular
weights are specific characteristics of PEG moieties relevant to pharmaceutical
applications.
In an antibody-drug conjugate, the link between the antibody and the cytotoxic
agent plays a critical role in the development of the ADC. Further, the nature of the
linker can significantly affect the potency, selectivity, and the pharmacokinetics of an
antibody-drug conjugate. A common feature of numerous linkers used to prepare
antibody-drug conjugates is their hydrophobicity – or their inability to dissolve in
water. In most cases, the average drug-to-antibody ratio or the number of drug
molecules per antibody does not exceed 3-4 drug molecules per antibody
molecule. Attempts to increase the drug-to-antibody ratio have often failed. This is
especially the case when both the cytotoxic agent and the linker are hydrophobic.
Other reasons may be caused due to aggregation of the antibody-drug conjugates,
the loss of affinity for the target antigen, and/or rapid clearance from circulation.
Many of the problems seen with hydrophobic linkers can be overcome by sulfonateor PEG-containing hydrophilic (aqueous-soluble) linkers which are characterized by
high solubility in both organic and aqueous solutions. The attachment of PEG-based
linkers to proteins and other biomolecules decreases aggregation and increases
solubility.
Furthermore, branched or multi-arm PEG linkers enable conjugation of hydrophobic
organic molecule drugs, such as a maytansinoid, at a higher ration of
drug-to-antibody ratio than hydrophobic SPDB and SMCC linkers used earlier without
triggering aggregation or loss of affinity of the resulting conjugate. This, in
turn, results in the ability to deliver a higher concentration of cytotoxic drugs into the
target cells per antibody binding event.
Related: Common Structures and Applications of PEGs

N-(ACID-PEG3)-N-BIS(PEG3-AMINE)


PEGs Conjugate a Versatile Approach of Antibody Drug.pdf - page 1/3
PEGs Conjugate a Versatile Approach of Antibody Drug.pdf - page 2/3
PEGs Conjugate a Versatile Approach of Antibody Drug.pdf - page 3/3

Related documents


pegs conjugate a versatile approach of antibody drug
cleavable vs non cleavable linkers in antibody drug conjugates
untitled pdf document
antibody drug1
doctoral proposal
learn all about elisa test procedure at antibody elisacom


Related keywords